Integrin ?6-targeted SPECT Imaging of Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
Summary
- Conditions
- Breast Cancer
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 25 years and 60 years
- Gender
- Both males and females
Description
Integrin ?6 associates with the survival and migration of breast cancer cells, which emerges as a predictor of reduced overall survival and worse prognosis. In this study, we developed an integrin ?6-targeted radiotracer 99mTc-RWY for SPECT imaging of breast cancer. The safety, biodistribution and r...
Integrin ?6 associates with the survival and migration of breast cancer cells, which emerges as a predictor of reduced overall survival and worse prognosis. In this study, we developed an integrin ?6-targeted radiotracer 99mTc-RWY for SPECT imaging of breast cancer. The safety, biodistribution and radiation dosimetry were studied in seven healthy volunteers, and the clinical potential of 99mTc-RWY was examined in two breast cancer patients. A single dose of 11.1 MBq/kg 99mTc-RWY was injected intravenously. Visual and semiquantitative methods were used to assess the SPECT/CT images. The routine Hematoxylin-Eosin (HE) staining and immunohistochemistry (IHC) staining were subsequently carried out to confirm the Integrin ?6 expression of tumors.
Tracking Information
- NCT #
- NCT04289532
- Collaborators
- China-Japan Union Hospital, Jilin University
- Sun Yat-sen University
- Investigators
- Not Provided
Get Well Soon